| Literature DB >> 32733246 |
Han Huang1, Jiansong Fang2, Xiude Fan3, Tatsunori Miyata3, Xiaoyue Hu1, Lihe Zhang1, Liangren Zhang1, Yimin Cui4, Zhenming Liu1, Xiaoqin Wu3.
Abstract
Traditional Chinese medicine (TCM) has been developed for thousands of years with its various biological activities. The interest in TCM in tumor prevention and treatment is rising with its synergistic effect on tumor cells and tumor immunosuppressive microenvironment (TIM). Characteristic of TCM fits well within the whole system and multi-target cancer treatment. Herein we discuss the underlying mechanisms of TCM actions in TIM via regulating immunosuppressive cells, including restoring the antigen presentation function of dendritic cells, enhancing NK cells-mediated killing activity, restraining the functions of myeloid cell-derived suppressor cells, and inhibiting cancer-associated fibroblasts. TCM also regulates tumor progression through enhancing immune response, preventing immune escape and inducing cell death of tumor cells, which triggers immune response in nearby cells. In addition, we discuss TCM in clinical applications and the advantages and disadvantages of TCM in cancer prevention and treatment, as well as current therapeutic challenges and strategies. It might be helpful for understanding the therapeutic potential of TCM for cancer in clinic.Entities:
Keywords: Traditional Chinese medicine (TCM); cancer cells; immune response; synergistic effect; tumor immunosuppressive microenvironment (TIM)
Year: 2020 PMID: 32733246 PMCID: PMC7360845 DOI: 10.3389/fphar.2020.01009
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Effect of TCM on crosstalk between tumor cells and innate immune cells.
| TCM | Tumor type | Effects on tumor cells | Main immune mechanisms | Ref. |
|---|---|---|---|---|
|
| ||||
| SL formula |
| Could suppress tumor growth in melanoma- bearing mice | Inhibiting the activation of STAT3 and STAT3-targeted immunosuppressive cytokines; increasing recruitment of DCs to melanoma tissues and spleens to enhance immune response. | ( |
| Am and/or Cp |
| Could enhance efficiency of DC-based vaccine against metastasis of 4T1 mammary carcinoma and the improved survival in mice | Increasing the expression of CD40, CD80 and CD86 in DCs and CD4+ and CD8+ T-cell proliferation | ( |
|
| ||||
| YPF |
| Could inhibit the growth of LLC and prolong the survival of tumor-bearing mice | Downregulating the protein levels of indoleamine 2,3-dioxygenase, TGF-β, and IL-10, which promoted tumor infiltration and killing capability of NK cells to LLC | ( |
| Lupeol |
| Could inhibit the proliferation of gastric cancer cells | Inducing the proliferation and promoting the killing power of NK cells through the upregulation of PFP, IFN-γ and CD107a in NK cells | ( |
| PSG-1 |
| Could inhibit S-180 cells | Increasing production of cytokines in Th1 cells and enhancing the cytotoxic activity of NK and CTL cells in mice by TLR4 | ( |
|
| ||||
| BFD formula |
| Could inhibit tumor growth and prolong the survival in mice | Blocking the crosstalk between TAMs and cancer cells through decreasing IL-10 and PD-L1 | ( |
| Baicalin (TCM monomer) |
| Could inhibit tumor growth of HCC | Inducing the repolarization of TAM to M1-like phenotype and promoting the production of pro-inflammatory cytokines in tumor; induction of autophagy and activation of RelB/p52 | ( |
|
| ||||
| SGJP formula | Patients with breast cancer, a murine model of 4T1 mammary cancer | MDSCs in patients with breast cancer were positively associated with cancer progression; Anti-tumor activity in mice | Had an inhibitory effect on Gr-1+ CD11b+ myeloid immunosuppressor cells; preventing MDSCs-induced IL-4, IL-13 and TGF-β expression and apoptosis of CD8+ T cells, as well as enhancing inflammatory responses of NKT cells by JAK-STAT signaling | ( |
SL, Styphnolobium japonicum (L.) Schott [Fabaceae] and Lonicera japonica Thunb [Caprifoliaceae]); Am, a mixed polysaccharide fractions from the root of Astragalus mongholicus Bunge [Fabaceae]; YPF, Yu-Ping-Feng; LLC, Lewis lung cancer; PSG-1, Ganoderma atrum polysaccharide; BFD, Bu Fei Decoction; NSCLC, non-small cell lung cancer; HCC, hepatocellular carcinoma; SGJP, Shugan Jianpi.
Effect of TCM on crosstalk between tumor cells and adaptive immune cells.
| TCM | Tumor type | Effects on tumor cells | Main mechanisms | Ref. |
|---|---|---|---|---|
|
| ||||
| SYY |
| Could inhibit growth and lung metastasis of liver cancer | Reducing the proportion of Treg and TGF-β1 expression in spleen, peripheral blood and tumor tissue | ( |
| GP |
| Could inhibit tumor growth of hepatocarcinoma | Reducing the frequency of CD4+CD25+ Tregs and Foxp3 expression, but increasing the ratio of Th1/2 cytokines in serum | ( |
|
| ||||
| Matrine |
| Could induce human ALL B-lymphocytes apoptosis | Upregulating the proapoptotic protein Bax while downregulating the anti-apoptotic protein Bcl-2 in human ALL B-lymphocytes | ( |
SYY, Songyou Yin); GP, Polysaccharide from Glycyrrhiza uralensis Fisch. ex DC. [Fabaceae]; ALL, acute lymphoblastic leukemia.
Inhibition of TCM on CAFs.
| TCM | Tumor type | Effects on tumor cells | Main mechanisms | Ref. |
|---|---|---|---|---|
| ARS and DHA |
| Could reverse breast cancer cell-CAFs from activated to inactivated state | Suppressing the TGF-β signaling to inhibit the interaction between tumor and TME. | ( |
| Curcumin (TCM monomer) |
| Could inhibit EMT and metastasis of pancreatic cancer cells | Inhibiting CAFs | ( |
| PP-1 (TCM component) |
| Could inhibit the growth of prostate-CAFs | Induction of autophagy by increasing the activation of Beclin-1 and LC3 | ( |
ART, artesunate; DHA, dihydroartemisinin; CAFs, cancer-associated fibroblasts; PP-1, Polysaccharide extracted from Polygonatum odoratum (Mill.) Druce [Asparagaceae].
Effect of TCM on immune response of tumor cells.
| TCM | Tumor type | Effects | Main mechanisms | Ref. | |
|---|---|---|---|---|---|
|
| |||||
| EPS |
| Could improve the expression of MHC-II, CD40, CD80, and CD86 in DCS cells and their ability of antigen uptake as well as secretion of IL-12 and TNF-α | Inhibiting phosphorylation of JAK2 and STAT3 and promoting the NF-κB signal pathway | ( | |
| ISD |
| Could suppress the development of cachexia caused by transplantable tumor and improve the survival of mice | Increasing MHC I/II expression in liver tissues | ( | |
|
| |||||
| BFD |
| Could inhibit tumor growth and prolong the survival in mice | Blocking the crosstalk between TAMs and cancer cells through decreasing IL-10 and PD-L1 | ( | |
| QYSL |
| Could inhibit tumor growth | High dose QYSL inhibited tumor growth by reducing PD-1 in spleen and PD-L1. | ( | |
| GQD |
| Could inhibit tumor growth of CRC and modulate the gut microbiome composition. | Combination therapy with GQD and anti-PD-1 induced the frequency of CD8+ T cells in tumor tissues and peripheral blood. They also increased IFN-γ and IL-2, but decreased PD-1. | ( | |
|
| |||||
| PZH |
| Could reduce the population and viability and sphere-forming capacity of HT-29 SP cells | Inhibiting ABCB1 and ABCG2 | ( | |
| Huaier |
| Could decrease the viabilities, numbers, sizes of mammospheres and the proportion of cells expressing CD44+/CD24-, and reduce the levels of stem cell markers | Partially dependent on the hedgehog pathway | ( | |
|
| Could inhibit the potential of spheroid formation and the population of ALDH−positive cell | Downregulating the Wnt/β−catenin pathway | ( | ||
EPS, the exopolysaccharide from an anamorph of Cordyceps sinensis; ISD, Invigorating Spleen and Detoxification Decoction; DCS, dendritic cell sarcoma; GQD, Gegen Qinlian decoction; CRC, colorectal cancer; BFD, Bu Fei Decoction; NSCLC, non-small cell lung cancer; QYSL, Qiyusanlong decoction; LLC, Lewis lung cancer; CSCs, cancer stem cells; PZH, Pien Tze Huang; Huaier, Trametes robiniophila Murr.; ALDH, aldehyde dehydrogenase.
Effect of TCM on cell death of tumor cells.
| TCM | Tumor type | Effects | Main mechanisms | Ref. |
|---|---|---|---|---|
|
| ||||
| AST |
| Could induce the extrinsic apoptotic cascade and caused cell cycle arrest | Regulating both mTOR and ERK signaling pathways, inhibition of NF-kappaB is a critical latter event | ( |
| LJGP |
| Could inhibit tumor growth and induce apoptosis by upregulating pro-apoptotic Bax, and downregulating anti-apoptotic Bcl-2 and IAP family members, as well as activation of caspase-3/9 | downregulating telomerase activity and prostaglandin E2 synthesis by decreasing COX-2 | ( |
| PHY906 |
| Could increase cell apoptosis | Increasing mouse FasL and human FasR expression | ( |
| YWKLF |
| The sera from rabbits orally administered with YWKLF induced cell apoptosis | Inducing mitochondrial dysfunction, increasing the expression of Fas and Bax, and reducing the mRNA levels of FasL | ( |
|
| ||||
| Bufalin |
| Could inhibit the proliferation, regulate the cell death program, and induce autophagy | Increasing TNF, MAPK and BECN-1 and ATG8, and decreasing Bcl-2 and Bid | ( |
| DHA-37 |
| Could trigger ACD in A549 cells and inhibit tumor growth | Activating the MAPK signal and upregulating HMGB1 | ( |
| PGB |
| Could induce ACD of A549 cells | Suppressing the AKT/mTOR pathway, and activating the AMPK and MAPK pathways | ( |
| FOJ and SSOJ |
| Could induce autophagy of A549 cells by upregulating protein levels of LC3-II and mRNA levels of Atg-3, Atg-7, Beclin-1 and LC3-II/I | Inhibiting the PI3K/Akt/mTOR signaling | ( |
|
| ||||
| Resibufogenin (TCM monomer) |
| Could suppress tumor growth and metastasis | Induction of necroptosis through increasing RIP3 and pMLKL | ( |
| Shikonin |
| Could induce necroptosis | Mediated by oxidative stress and RIP1 signaling | ( |
|
| ||||
| SB |
| Could suppress proliferation and angiogenesis, and increase apoptosis and autophagy | ER stress-, intrinsic mitochondrial-, P38/SIRT1-regulated cell apoptosis through G2/M phase arrest and extrinsic Fas/FasL-mediated pathways | ( |
| HLP |
| Could induce apoptosis and ACD in A375 cells | Increasing the caspases cleavages, Bcl-2, and Fas/FasL activation and ATG5, Beclin1, and LC3-II | ( |
| Shikonin |
| Could trigger RIP1- and RIP3-dependent necroptosis and autophagy, and stimulate the derived vaccine efficacy | Enhancing the surface DMAP activity and DC activation | ( |
AST, The total saponins of Astragalus mongholicus Bunge [Fabaceae]; CRC, colorectal cancer; LJGP, Glycoprotein isolated from Laminaria japonica; YWKLF, a herbal medicine formula Yang Wei Kang Liu; DHA-37, Dihydroartemisinin; ACD, autophagic cell death; HMGB1, high mobility group protein; PGB, the platycoside-containing butanol fraction of PG; FOJ, Flavonoids; SSOJ, steroidal saponins; OJ, Ophiopogon japonicus (Thunb.) Ker Gawl. [Asparagaceae]; SB, Scutellaria barbata D.Don [Lamiaceae]; HLP, Hibiscus leaf polyphenolic.
TCM in clinical applications.
| TCM | Patients | Effects | Main mechanisms | Ref. |
|---|---|---|---|---|
| YWKLF (formula, orally) | Stage IV gastric cancer, 123 patients | Prolonged the survival time compared to chemotherapy alone | The sera from rabbits orally administered with YWKLF induced cell apoptosis in human gastric cancer MGC-803 cells through inducing mitochondrial dysfunction, increasing the expression of Fas and Bax, as well as reducing the mRNA of FasL | ( |
| JPBS (formula, orally) combined with chemotherapy | Gastric cancer, 26 studies with 3098 individuals | Improved the efficiency of clinical curative effect and QOL of patients | Increase the levels of CD3+, CD4+, CD4+/CD8+, NK+, and macrophages in patient serum | ( |
| Cinobufacini (TCM monomer, injection) and herbal decoction (formula, orally) maintenance therapy | NSCLC, 64 patients | Improved QOL and had higher 1-year survival of patients | Not mentioned | ( |
| TCM decoction (formula, orally), maintenance therapy | NSCLC, 106 patients | Improved 3-month PFS and QOL in patients | Not mentioned | ( |
| XAP (TCM component, injection) | HCC, 68 patients | Improved immediate therapeutic efficacy and QOL and prolonged the PFS in patients | Increasing levels of CD3+, CD4+and CD4+/CD8+ in the peripheral blood | ( |
| BSJPR (formula) | primary liver cancer, 117 patients | Improved the half-year survival rate and QOL of patients | Increasing MHC class II (CD14+/HLA-DR), IFN-γ and IL-12 in monocytes | ( |
| YJQR (formula, orally) combined with endocrine therapy | APC, 44 patients | Increased PSA, f-PSA and Hb in serum, and improved QOL and immune function of patients | Increasing levels of CD3+, CD4+ and CD4+/CD8+ and NK cell in serum | ( |
YWKLF, Yang Wei Kang Liu formula; JPBS, Jianpi Bushen; QOL, quality of life; herbal decoction, benefiting Qi and Yin and detoxication recipe; NSCLC, non-small cell lung cancer; PFS, progression-free survival; XAP, Xiaoaiping; HCC, hepatocellular carcinoma; BSJPR, Bushen Jianpi Recipe; TACE, transcatheter arterial chemoembolization; YJQR, Yiqi Jiedu Quyu Recipe; APC, advanced prostate cancer; PSA, prostate specific antigen; f-PSA, free PSA; Hb, hemoglobin.
Figure 1Chemical structures of multiple TCM monomers.
Figure 2Underlying mechanism for effect of TCM on tumor cells and TIM.